PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers

Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Teyssonneau, Diego, Thiery-Vuillemin, Antoine, Dariane, Charles, Barret, Eric, Beauval, Jean-Baptiste, Brureau, Laurent, Créhange, Gilles, Fiard, Gaëlle, Fromont, Gaëlle, Gauthé, Mathieu, Ruffion, Alain, Renard-Penna, Raphaële, Mathieu, Romain, Sargos, Paul, Rouprêt, Morgan, Ploussard, Guillaume, Roubaud, Guilhem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952857/
https://www.ncbi.nlm.nih.gov/pubmed/35330059
http://dx.doi.org/10.3390/jcm11061734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952857/
https://www.ncbi.nlm.nih.gov/pubmed/35330059
http://dx.doi.org/10.3390/jcm11061734

Ejemplares similares